Light Axis Targeting May Alter Melatonin and Memory in Mild Cognitive Impairment
A Mount Sinai trial tests whether directing light to eye periphery vs. center differently suppresses melatonin in MCI patients and healthy controls.
Summary
Researchers at the Icahn School of Medicine at Mount Sinai conducted a completed clinical trial exploring how the angle of light entering the eye affects melatonin suppression and memory in people with mild cognitive impairment (MCI). The study compared 24 MCI participants with 24 healthy, age-matched controls, exposing them to blue light, green light, and a dim-light control condition directed either along the eye's central visual axis (on-axis, toward the fovea) or toward the eye's periphery (off-axis). The thickness of the macular pigment layer at the back of the eye was also measured. The hypothesis is that circadian photoreception — which governs melatonin timing and sleep — may be compromised or modifiable in MCI, and that optimizing light delivery angle could represent a non-pharmacological tool for improving circadian health in cognitively vulnerable older adults.
Detailed Summary
Disrupted circadian rhythms and poor sleep are both risk factors for cognitive decline and are commonly observed in people with Alzheimer's disease and mild cognitive impairment. Understanding how the aging eye processes light — and whether that processing can be optimized — is emerging as a meaningful frontier in brain health and dementia prevention.
This completed trial from the Icahn School of Medicine at Mount Sinai investigated a specific and underexplored mechanism: whether directing light on-axis (toward the fovea, the center of the retina) versus off-axis (toward the peripheral retina) produces different degrees of melatonin suppression. Melatonin suppression is the primary circadian signal that resets the body clock, and it is driven largely by intrinsically photosensitive retinal ganglion cells, which are distributed unevenly across the retina.
The trial enrolled 24 participants with mild cognitive impairment and 24 healthy age-matched controls. Participants underwent blue light, green light, and dim-light control conditions under both on-axis and off-axis illumination. Macular pigment optical density — which filters short-wavelength blue light reaching deeper retinal layers — was also measured to assess whether eye pigment thickness influences the circadian light response.
The implications are clinically significant. If peripheral retinal stimulation proves more effective at suppressing melatonin, or if MCI patients show a blunted or altered response, this could lead to precisely targeted lighting interventions — adjustable fixtures or wearable devices — designed to reinforce circadian entrainment without pharmacological intervention. Such tools could be especially valuable in care settings for older adults at risk of dementia.
Caveats are meaningful: this summary is based solely on the trial registration abstract, and no published results were available. The small sample size and phase-NA design limit generalizability, and outcome data remain unpublished as of this review.
Key Findings
- On-axis vs. off-axis light direction may produce meaningfully different melatonin suppression responses in older adults.
- Macular pigment thickness is being assessed as a potential moderator of circadian light sensitivity.
- MCI patients and healthy age-matched controls are compared to detect disease-related differences in circadian photoreception.
- Blue and green light wavelengths are tested separately to identify which best activates circadian pathways via off-axis delivery.
- Non-pharmacological light targeting could become a practical tool for improving sleep and cognition in at-risk older adults.
Methodology
Completed randomized controlled trial with 48 participants (24 MCI, 24 healthy age-matched controls) at the Icahn School of Medicine at Mount Sinai. Participants were exposed to blue light, green light, and dim-light control conditions under both on-axis and off-axis illumination protocols. Outcomes included melatonin suppression levels and macular pigment optical density measurements.
Study Limitations
This summary is based on the trial registration abstract only; full methodology and results are not yet publicly available in a peer-reviewed publication. The sample size of 48 participants is small, limiting statistical power and generalizability. No efficacy outcomes or adverse event data are reported in the available registration record.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: